ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis
USA - NASDAQ:ITOS - US46565G1040 - Common Stock
10.15 USD
+0.02 (+0.2%)
10.17 USD
+0.02 (+0.2%)
ITOS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While ITOS has a great health rating, there are worries on its profitability. ITOS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ITOS had negative earnings in the past year.
In the past year ITOS has reported a negative cash flow from operations.
In multiple years ITOS reported negative net income over the last 5 years.
ITOS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ITOS's Return On Assets of -21.57% is fine compared to the rest of the industry. ITOS outperforms 75.83% of its industry peers.
With a decent Return On Equity value of -27.22%, ITOS is doing good in the industry, outperforming 79.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| ROIC | N/A |
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITOS has more shares outstanding than it did 1 year ago.
ITOS has more shares outstanding than it did 5 years ago.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ITOS has an Altman-Z score of 1.90. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.90, ITOS is doing good in the industry, outperforming 66.79% of the companies in the same industry.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.9 |
ROIC/WACCN/A
WACC9.73%
2.3 Liquidity
ITOS has a Current Ratio of 7.53. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
ITOS has a better Current ratio (7.53) than 71.40% of its industry peers.
ITOS has a Quick Ratio of 7.53. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ITOS (7.53) is better than 71.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 |
3. Growth
3.1 Past
ITOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.67%.
ITOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 177.89%.
The Revenue for ITOS have been decreasing by -53.35% on average. This is quite bad
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
ITOS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.35% yearly.
ITOS is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.
Also next year ITOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ITOS's earnings are expected to grow with 13.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y13.13%
5. Dividend
5.1 Amount
No dividends for ITOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.15
+0.02 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.81%
Inst Owner Change-14.25%
Ins Owners1.18%
Ins Owner Change-15.43%
Market Cap448.73M
Revenue(TTM)35.00M
Net Income(TTM)-134.41M
Analysts50
Price Target10.56 (4.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.81%
Min EPS beat(2)-39.15%
Max EPS beat(2)17.53%
EPS beat(4)2
Avg EPS beat(4)-8.08%
Min EPS beat(4)-39.15%
Max EPS beat(4)17.53%
EPS beat(8)6
Avg EPS beat(8)14.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.92%
PT rev (3m)-11.92%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-10.11%
EPS NY rev (1m)-10.29%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.91 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.31
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.79
BVpS11.17
TBVpS11.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.87% | ||
| Cap/Sales | 1.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 | ||
| Altman-Z | 1.9 |
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.37%
OCF growth 3YN/A
OCF growth 5YN/A
ITEOS THERAPEUTICS INC / ITOS FAQ
What is the fundamental rating for ITOS stock?
ChartMill assigns a fundamental rating of 3 / 10 to ITOS.
What is the valuation status of ITEOS THERAPEUTICS INC (ITOS) stock?
ChartMill assigns a valuation rating of 0 / 10 to ITEOS THERAPEUTICS INC (ITOS). This can be considered as Overvalued.
What is the profitability of ITOS stock?
ITEOS THERAPEUTICS INC (ITOS) has a profitability rating of 1 / 10.
How financially healthy is ITEOS THERAPEUTICS INC?
The financial health rating of ITEOS THERAPEUTICS INC (ITOS) is 7 / 10.
What is the expected EPS growth for ITEOS THERAPEUTICS INC (ITOS) stock?
The Earnings per Share (EPS) of ITEOS THERAPEUTICS INC (ITOS) is expected to decline by -7.51% in the next year.